Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Autor: Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin, Tuphan K. Dolai, Dinesh K. Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Michele Cavo, Yi Chai, Jacqueline Jeha, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson, Sebastian Grosicki

Publikováno v: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)

Abstract Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in t

Externí odkaz: https://doaj.org/article/20b9da9076424d1f8dc1d21eef7bc3c4

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Autor: Vadim A Doronin, Maryana Simonova, Philippe Moreau, Ludek Pour, Larry D. Anderson, Sosana Delimpasi, Nizar J. Bahlis, Hang Quach, Reuben Benjamin, Christopher P. Venner, Thierry Facon, Jatin P. Shah, Halyna Pylypenko, Mamta Garg, Roman Hájek, Maria Gavriatopoulou, Holger W. Auner, Meletios A. Dimopoulos, Irina Kryachok, Maria V. Mateos, Michele Cavo, Ganna Usenko, Sundar Jagannath, Moshe Yair Levy, Michael Kauffman, Sharon Shacham, Sebastian Grosicki, Xavier Leleu, Ivan Spicka, Melina Arazy, Yi Chai, Dinesh Kumar Sinha, Ashraf Z. Badros, Don A. Stevens, Paul G. Richardson, Tuphan Kanti Dolai

Publikováno v: Blood. 136:48-50

Introduction Selinexor is a first-in-class, oral, potent selective inhibitor of nuclear export (SINE) which blocks XPO1, forcing the nuclear retention and activation of tumor suppressor proteins, leading to cancer cell apoptosis. Selinexor has demons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::92b852e8d6b07ea1304876ee386b0f29
https://doi.org/10.1182/blood-2020-138391

Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis

Autor: Renata Cabral, Juan Carlos Caballero, Sara Alonso, Julio Dávila, Monica Cabrero, Dolores Caballero, Lourdes Vásquez, Fermin Sánchez-Guijo, Lucia López, Maria C. Cañizo, Maria V. Mateos, Marcos González

Publikováno v: Hematology Reports, Vol 6, Iss 4 (2014)

Detailed knowledge about differentiation syndrome (DS) has remained limited. There are 2 large studies conducted by the Spanish workgroup PETHEMA (Programa Español de Tratamientos en Hematología; Spanish Program on Hematology Treatments) and the

Externí odkaz: https://doaj.org/article/64cefe7f25e74b34be1008234ca49d70

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Autor: Laura Rosiñol, Meral Beksac, Elena Zamagni, Niels W. C. J. Van de Donk, Kenneth C. Anderson, Ashraf Badros, Jo Caers, Michele Cavo, Meletios‐Athanasios Dimopoulos, Angela Dispenzieri, Hermann Einsele, Monika Engelhardt, Carlos Fernández de Larrea, Gösta Gahrton, Francesca Gay, Roman Hájek, Vania Hungria, Artur Jurczyszyn, Nicolaus Kröger, Robert A. Kyle, Fernando Leal da Costa, Xavier Leleu, Suzanne Lentzsch, Maria V. Mateos, Giampaolo Merlini, Mohamad Mohty, Philippe Moreau, Leo Rasche, Donna Reece, Orhan Sezer, Pieter Sonneveld, Saad Z. Usmani, Karin Vanderkerken, David H. Vesole, Anders Waage, Sonja Zweegman, Paul G. Richardson, Joan Bladé

Publikováno v: Rosiñol, L, Beksac, M, Zamagni, E, Van de Donk, N W C J, Anderson, K C, Badros, A, Caers, J, Cavo, M, Dimopoulos, M A, Dispenzieri, A, Einsele, H, Engelhardt, M, Fernández de Larrea, C, Gahrton, G, Gay, F, Hájek, R, Hungria, V, Jurczyszyn, A, Kröger, N, Kyle, R A, Leal da Costa, F, Leleu, X, Lentzsch, S, Mateos, M V, Merlini, G, Mohty, M, Moreau, P, Rasche, L, Reece, D, Sezer, O, Sonneveld, P, Usmani, S Z, Vanderkerken, K, Vesole, D H, Waage, A, Zweegman, S, Richardson, P G & Bladé, J 2021, ' Expert review on soft-tissue plasmacytomas in multiple myeloma : definition, disease assessment and treatment considerations ', British Journal of Haematology, vol. 194, no. 3, pp. 496-507 . https://doi.org/10.1111/bjh.17338

In this review, two types of soft-tissue involvement in multiple myeloma are defined: (i) extramedullary (EMD) with haematogenous spread involving only soft tissues and (ii) paraskeletal (PS) with tumour masses arising from skeletal lesions. The inci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::808c0e8196dcdf4a4756120a00827be9
http://hdl.handle.net/11585/865197

Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?

Autor: Shaji Kumar, Alessandro Gozzetti, Roman Hájek, Artur Jurczyszyn, Gabor Mikala, David H. Vesole, Joseph Mikhael, Maria V. Mateos, Evangelos Terpos, Anna Suska, Marta Szostek, Hari Parameswaran, Thierry Facon, Jorge J. Castillo

Publikováno v: Clinical Hematology International
Clinical Hematology International, Vol 2, Iss 4 (2020)

Plasma cell leukemia (PCL) is an aggressive hematological malignancy characterized by an uncontrolled clonal proliferation of plasma cells (PCs) in the bone marrow and peripheral blood. PCL has been defined by an absolute number of circulating PCs ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::155501dc8da99a78200d7df8b2b4b9ed
https://hdl.handle.net/11365/1116448